| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(10 years from now) | |
Camzyos is owned by Bristol.
Camzyos contains Mavacamten.
Camzyos has a total of 2 drug patents out of which 0 drug patents have expired.
Camzyos was authorised for market use on 28 April, 2022.
Camzyos is available in capsule;oral dosage forms.
Camzyos can be used as treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms.
Drug patent challenges can be filed against Camzyos from 28 April, 2026.
The generics of Camzyos are possible to be released after 19 June, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-398) | Apr 28, 2029 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2027 |
| M(M-297) | Jun 15, 2026 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 28 April, 2026
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE;ORAL
CAMZYOS family patents
